Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Stem Cells Transl Med ; 10(1): 5-13, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-32856432

RESUMEN

This perspective from a Regenerative Medicine Manufacturing Society working group highlights regenerative medicine therapeutic opportunities for fighting COVID-19. This article addresses why SARS-CoV-2 is so different from other viruses and how regenerative medicine is poised to deliver new therapeutic opportunities to battle COVID-19. We describe animal models that depict the mechanism of action for COVID-19 and that may help identify new treatments. Additionally, organoid platforms that can recapitulate some of the physiological properties of human organ systems, such as the lungs and the heart, are discussed as potential platforms that may prove useful in rapidly screening new drugs and identifying at-risk patients. This article critically evaluates some of the promising regenerative medicine-based therapies for treating COVID-19 and presents some of the collective technologies and resources that the scientific community currently has available to confront this pandemic.


Asunto(s)
COVID-19/terapia , Medicina Regenerativa/métodos , Medicina Regenerativa/tendencias , Animales , Humanos , SARS-CoV-2
2.
Stem Cells Transl Med ; 9(7): 728-733, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32222115

RESUMEN

The Regenerative Medicine Manufacturing Society (RMMS) is the first and only professional society dedicated toward advancing manufacturing solutions for the field of regenerative medicine. RMMS's vision is to provide greater patient access to regenerative medicine therapies through innovative manufacturing solutions. Our mission is to identify unmet needs and gaps in regenerative medicine manufacturing and catalyze the generation of new ideas and solutions by working with private and public stakeholders. We aim to accomplish our mission through outreach and education programs and securing grants for public-private collaborations in regenerative medicine manufacturing. This perspective will cover four impact areas that the society's leadership team has identified as critical: (a) cell manufacturing and scale-up/out, respectively, for allogeneic and autologous cell therapies, (b) standards for regenerative medicine, (c) 3D bioprinting, and (d) artificial intelligence-enabled automation. In addition to covering these areas and ways in which the society intends to advance the field in a collaborative nature, we will also discuss education and training. Education and training is an area that is critical for communicating the current challenges, developing solutions to accelerate the commercialization of the latest technological advances, and growing the workforce in the rapidly expanding sector of regenerative medicine.


Asunto(s)
Inteligencia Artificial/normas , Automatización/métodos , Bioimpresión/métodos , Educación/métodos , Impresión Tridimensional/normas , Medicina Regenerativa/métodos , Ingeniería de Tejidos/métodos , Humanos , Resultado del Tratamiento
3.
J Patient Exp ; 6(1): 62-67, 2019 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31236453

RESUMEN

BACKGROUND: Research has shown that inpatients may not accurately report interacting with a pharmacist. OBJECTIVE: To determine accuracy of patients' recollection of meeting with a pharmacist at 2 acute care teaching hospitals in Edmonton, Alberta, Canada. METHODS: Retrospective review of 391 surveyed patients discharged from April 2013 to March 2014. Responses to meeting a pharmacist (yes/no) were compared with 2 reference standards: pharmacist documentation in patient charts and pharmacist clinical workload data. Sensitivity, specificity, positive predictive, and negative predictive values were calculated. RESULTS: One hundred ninety-five (49.9%) respondents reported meeting with a pharmacist. Of these, 71 (36.4%) had corresponding pharmacist chart documentation. Of the 196 respondents who reported not speaking with a pharmacist, 73 (37.2%) had documentation present. Compared with patient charts, sensitivity and specificity were 49.3% and 49.8%, respectively. Positive and negative predictive values were 36.4% and 62.8%, respectively. Similar results were seen in comparison with the workload data. CONCLUSIONS: Patients often inaccurately reported meeting with a pharmacist in the acute care setting. The results are useful for pharmacist training, patient education, and for refinement of the current survey question.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA